英夫利昔单抗治疗难治性川崎病伴冠状动脉瘤。

Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

作者信息

Oishi Taku, Fujieda Mikiya, Shiraishi Taisuke, Ono Miki, Inoue Kazuo, Takahashi Akiyoshi, Ogura Hideo, Wakiguchi Hiroshi

机构信息

Department of Pediatrics, Kochi National Hospital, Kochi, Japan.

出版信息

Circ J. 2008 May;72(5):850-2. doi: 10.1253/circj.72.850.

DOI:10.1253/circj.72.850

PMID:18441471

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.

摘要

肿瘤坏死因子-α（TNF-α）被认为是诱发包括川崎病（KD）冠状动脉瘤（CA）在内的血管炎的因素之一，因为与未患冠状动脉瘤的患者相比，患冠状动脉瘤的川崎病患者血液中TNF-α的浓度更高。因此，一名1个月大患有难治性川崎病并伴有冠状动脉瘤的女童接受了抗TNF-α药物（英夫利昔单抗）治疗，随后冠状动脉瘤病情改善，川崎病在发病20个月后得到控制，且未出现并发症。